Our Pipeline

Lenzilumab (anti-GM-CSF mAb)

Prophylaxis CAR-T-therapy-induced serious A/Es 1

(CAR-T optimization)

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase complete
Phase I Phase complete
Phase II Phase in progress
Phase III Phase not started
BLA Phase not started

CMML 2

(monotherapy in salvage patients - fully enrolled)

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase complete
Phase I Phase in progress
Phase II Phase not started
Phase III Phase not started
BLA Phase not started

Ifabotuzumab (anti-EphA3 mAb)

GBM

(monotherapy in salvage patients)

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase complete
Phase I Phase in progress
Phase II Phase not started
Phase III Phase not started
BLA Phase not started

Antibody drug conjugate

(currently in animal testing for various cancers)

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase in progress
Phase I Phase not started
Phase II Phase not started
Phase III Phase not started
BLA Phase not started

CAR-T construct potential for various cancers

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase in progress
Phase I Phase not started
Phase II Phase not started
Phase III Phase not started
BLA Phase not started

HGEN005 (anti-EMR1 mAb)

Eosinophilic asthma
Eosinophilic esophagitis
Eosinophilic granulomatosis with polyangiitis

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase in progress
Phase I Phase not started
Phase II Phase not started
Phase III Phase not started
BLA Phase not started

CAR-T construct potential for eosinophilic leukemia

Preclinical Phase I Phase II Phase III BLA
Preclinical Phase in progress
Phase I Phase not started
Phase II Phase not started
Phase III Phase not started
BLA Phase not started
  1. Phase Ib/II potential pivotal study
  2. Potential pivot to JMML on interim CMML data